• Mersana Therapeutics to Present at Upcoming Investor Conferences

    Source: Nasdaq GlobeNewswire / 02 Feb 2023 08:00:01   America/New_York

    CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences:

    Guggenheim Oncology Conference
    Format:Fireside Chat
    Date/Time:Wednesday, February 8, 2023, at 2:10 p.m. Eastern Time


    SVB Securities Global Biopharma Conference
    Format:Fireside Chat
    Date/TimeWednesday, February 15, 2023, at 1:00 p.m. Eastern Time


    Cowen 43rd Annual Health Care Conference
    Format:Panel Discussion
    Date/Time:Wednesday, March 8, 2023, at 9:10 a.m. Eastern Time


    Oppenheimer 33rd Annual Healthcare Conference
    Format:Presentation
    Date/Time:Tuesday, March 14, 2023, at 12:00 p.m. Eastern Time

    Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.

    About Mersana Therapeutics
    Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

    Contact:
    Jason Fredette
    617-498-0020
    jason.fredette@mersana.com


    Primary Logo

Share on,